S15:02 Dapirolizumab pegol and flare reduction in patients with SLE in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice
Richard Furie(Hofstra University), C. Stach(Merck KGaA, Darmstadt (Germany)), Annette Nelde(Biogen (Switzerland)), Marilyn C. Pike(Bethesda Hospital), Eric F Morand(Monash University), George Bertsias(University of Crete), Marta Mosca(University of Pisa), Edward M Vital(University of Leeds), Vanessa Taeib(UCB Pharma (France)), L. M. Carter(University of Leeds)
Cited by 0
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
|Circulation|2002|652
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478